Hatchtech board and management changes
22-Apr-2009
- Australia
biotechnology company Hatchtech Pty Ltd announced that Paul MacLeman has resigned as Chief Executive Officer and Director. The company congratulates Dr MacLeman who is leaving to take up the CEO role at a high profile publicly listed biotechnology company.
Since joining Hatchtech in 2005, Dr MacLeman and the board, management and advisors, have moved the company from research to Phase II human trials of the single treatment head lice control product DeOvo™. This is a new generation low-toxicity lousicide that is expected to be the first highly effective treatment for human head lice.
Dr MacLeman will continue with Hatchtech until the end of April.
Other news from the department people
